Vaccine (Inactivated vaccine) · Immune activation · developed by Sanofi
IIV-HD is an intramuscularly administered suspension studied for active immunization against influenza in healthy volunteers, with COVID-19 immunization also listed among the trial conditions.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07890454 | Phase 3 | Immunization | Recruiting | SNY |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID-19 ImmunizationHealthy VolunteersImmunizationInfluenza Immunization
Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.
See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SNY catalysts and pipeline →